The one available analyst rating on the shares is buy.
The average consensus recommendation for the biotechnology and medical research peer group is buy.
Wall Street's median 12-month price target for CEL-SCI Corp is $10.00, about 549.4% above its August 14 closing price of $1.54.
Quarterly results
US cancer immunotherapy developer's fiscal Q3 net loss was unchanged from the prior year.
Basic and diluted net loss per share narrowed to $0.47 from $1.36 a year ago.
The company advanced Multikine with a new Saudi Arabia partnership and a global registration study.
Key result drivers
Biomarker strategy - The company said a peer-reviewed study identified biomarkers for selecting patients most likely to benefit from Multikine, forming the basis for the upcoming global registration study.
Saudi Arabia partnership - The company signed a partnership with Amarox to advance Multikine approval and commercialization in Saudi Arabia, including pursuit of Breakthrough Designation.
CVM•
